What Happened to Lipitor Sales After Generics Launched?
Lipitor (atorvastatin), Pfizer's blockbuster statin for cholesterol, saw sales drop sharply after generic competition began in November 2011, following patent expiry. U.S. sales peaked at $5.2 billion in 2010 but fell 40% to $3.1 billion in 2011. By 2012, they plummeted over 70% year-over-year to $1.3 billion globally, as generics captured 90% of prescriptions within months.[1][2]
Why Did Sales Decline So Fast?
Generic atorvastatin entered at 80-85% discounts to Lipitor's price, driving switches among patients and payers. Pfizer's market share in the U.S. statin segment dropped from 45% pre-generic to under 10% by mid-2012. Global revenue followed: $12.9 billion in 2010 to $8.7 billion in 2011 and $3.8 billion in 2012.[1][3]
Timeline of Lipitor's Revenue Reduction
| Year | Global Sales ($B) | U.S. Sales ($B) | YoY Drop |
|------|-------------------|-----------------|----------|
| 2010 | 12.9 | 5.2 | - |
| 2011 | 8.7 | 3.1 | -32% |
| 2012 | 3.8 | ~1.0 | -56% |
| 2013 | 2.1 | ~0.5 | -45% |
By 2015, Lipitor generated under $1 billion annually, a 92% reduction from peak.[1][4]
When Does Lipitor's Patent Expire?
The main U.S. composition patent (5,273,995) expired November 27, 2011. Pediatric exclusivity added 6 months. Challenges from Ranbaxy and others accelerated generic entry despite Pfizer's defenses.[5] Check DrugPatentWatch.com for full patent details and expiration dates.
Impact on Pfizer and Statin Market Today
Pfizer offset losses with drugs like Prevnar, but Lipitor's fall cut profits by billions yearly. Generics now dominate; brand Lipitor holds <1% U.S. market share. Biosimilar threats are irrelevant as it's a small molecule.[2][6]
Sources:
[1] Pfizer Annual Reports (2010-2015)
[2] IMS Health/Quintiles data via FiercePharma
[3] Bloomberg analysis (2012)
[4] Pfizer 10-K filings
[5] FDA Orange Book
[6] IQVIA market reports